Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Iron chelators have been reported to induce apoptosis and cell cycle arrest in cancer cells. Recent studies suggest broad and selective antitumor activity of the new iron chelator, di‐2‐pyridylketone‐4,4‐dimethyl‐3‐thiosemicarbazone (Dp44mT; Whitnall et al., Proc Natl Acad Sci USA 2006;103:14901–14906). However, little is known concerning its effects on hematological malignancies. Using acute leukemia cells, the effect of Dp44mT on apoptosis, cell cycle, caspase‐3 activation, and mitochondrial trans‐membrane potential has been examined by flow cytometry. Dp44mT acted to induce a G 1/S arrest in NB4 promyelocytic leukemia cells at low concentrations (0.5–2.5 μM), being far more effective than the clinically used chelator, desferrioxamine (DFO). Moreover, Dp44mT induced apoptosis of NB4 cells in a dose‐ and time‐dependent manner with markedly less effect on nonproliferating cells. The apoptosis‐inducing activity of Dp44mT was significantly more effective than DFO. Furthermore, this study also showed that Dp44mT had broad activity, inducing apoptosis in several types of acute leukemia and also multiple myeloma cell lines. Additional studies examining the cytotoxic mechanisms of Dp44mT showed that a reduction in the mitochondrial trans‐membrane potential and caspase‐3 activation could be involved in the mechanism of apoptosis. Our results suggest that Dp44mT possesses potential as an effective cytotoxic agent for the chemotherapeutic treatment of acute leukemia. Am. J. Hematol. 2009. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
Self-citationA Cell-Surface Receptor for Lipocalin 24p3 Selectively Mediates Apoptosis and Iron Uptake
Devireddy, L. R., Gazin, C., Zhu, X., & Green, M. R. (2005) · Cell · doi:10.1016/j.cell.2005.10.027 · Cited by 672
Asou, H., Tashiro, S., Hamamoto, K., Otsuji, A., Kita, K., & Kamada, N. (1991) · Blood · doi:10.1182/blood.v77.9.2031.2031 · Cited by 291
Chelators at the cancer coalface: Desferrioxamine to Triapine and beyond
Yu, Y., Wong, J., Lovejoy, D. B., Kalinowski, D. S., & Richardson, D. R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1954 · Cited by 195 · cited 1×
“DFO is a relatively large hexadentate chelator that is rather hydrophilic with a molecular weight of 657 [27,44].”
BackgroundSelf-citationKalinowski, D. S., & Richardson, D. R. (2007) · Chemical Research in Toxicology · doi:10.1021/tx700039c · Cited by 145 · cited 2×
“, DNA synthesis) and the second punch is mediated by the generation of cytotoxic reactive oxygen species [37].”
BackgroundSelf-citationCell Permeable Iron Chelators as Potential Cancer Chemotherapeutic Agents
Pahl, P. M. B., & Horwitz, L. D. (2005) · Cancer Investigation · doi:10.1080/07357900500359976 · Cited by 40
Cited by
Yu, Y., Kalinowski, D. S., Kovacevic, Z., Siafakas, A. R., Jansson, P. J., Stefani, C., Lovejoy, D. B., Sharpe, P. C., Bernhardt, P. V., & Richardson, D. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900552r · Cited by 397
Self-citationSynthetic and natural iron chelators: Therapeutic potential and clinical use
Hatcher, H. C., Singh, R. N., Torti, F. M., & Torti, S. V. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.121 · Cited by 242
Bendova, P., Mackova, E., Haskova, P., Vavrova, A., Jirkovsky, E., Sterba, M., Popelova, O., Kalinowski, D. S., Kovarikova, P., Vavrova, K., et al. (2010) · Chemical Research in Toxicology · doi:10.1021/tx100125t · Cited by 73
Iron Chelators with Topoisomerase-Inhibitory Activity and Their Anticancer Applications
Rao, V. A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4877 · Cited by 37
Metadata
- Authors
- Noulsri, E., Richardson, D. R., Lerdwana, S., Fucharoen, S., Yamagishi, T., Kalinowski, D. S., & Pattanapanyasat, K.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2009-01-12
- Volume
- 84
- Issue
- 3
- Pages
- 170-176
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W1978071562
- Cited by
- 89
- References
- 6
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. https://app.cochat.ai/papers/10.1002/ajh.21350
- The paper
- Noulsri, E., Richardson, D. R., Lerdwana, S., Fucharoen, S., Yamagishi, T., Kalinowski, D. S., & Pattanapanyasat, K. (2009). Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. American Journal of Hematology. https://doi.org/10.1002/ajh.21350
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.